(Reuters) – Merck & Co Inc said on Wednesday that the<\/p>\n
expected a broad about its drug study data for<\/p>\n
Zetia cholesterol will be available in 2014 instead of the<\/p>\n
2013.<\/p>\n
essay on 18,000 patients, closely followed and<\/p>\n
called IMPROVE-IT, it was designed to assess whether combining Zetia<\/p>\n
with the oldest of so-called Merck cholesterol drug<\/p>\n
Zocor is more effective in reducing heart attacks and<\/p>\n
strokes (CVA) than Zocor alone.<\/p>\n
Zocor, known generically as simvastatin, is one<\/p>\n
similar to Lipitor from Pfizer Inc. Zetia Statin reduces the<\/p>\n
cholesterol using a method different. Merck Vytorin combines<\/p>\n
both drugs in a single pill, and is the product that is<\/p>\n
you are evaluating in the trial.<\/p>\n
the questions about combination therapy came<\/p>\n
then of that data on a prior trial, known as ENHANCE<\/p>\n
they thrown that Vytorin was no more effective at reducing plaque<\/p>\n
in the carotid artery that Zocor only and not respond the<\/p>\n
question about whether adding Zetia more decreased the rate of heart attacks.<\/p>\n
and while Vytorin Yes appeared better in decreasing of the<\/p>\n
’bad’ LDL cholesterol, did not generate major changes in other<\/p>\n
key measurements in patients with a hereditary form of<\/p>\n
high cholesterol known as hypercholesterolemia family.<\/p>\n
is stipulated that the IMPROVE-IT trial ends once that<\/p>\n
5,250 episodes clinical, as attacks have reported<\/p>\n
cardiac or LCA.<\/p>\n
in March of this year, driver Security Committee of<\/p>\n
trial, an independent, entity data completed a second<\/p>\n
preliminary efficacy analysis and recommended not to change the design<\/p>\n
of the Studie. und sagte, dass er plante, \u00fcberpr\u00fcfen Sie die Daten wieder in<\/p>\n
etwa neun Monate.<\/p>\n
Merck darauf hingewiesen, dass die Revision nun auf verschoben hatte<\/p>\n
M\u00e4rz von 2013. basierend auf der aktuellen Rate, bei der sich<\/p>\n
Episoden, Unterrichtung, die Firma sagte, es erwartet, dass die Anzahl<\/p>\n
Ziel wird im Jahr 2014 erreicht werden.<\/p>\n","protected":false},"excerpt":{"rendered":"
(Reuters) – Merck & Co Inc said on Wednesday that the expected a broad about its drug study data for Zetia cholesterol will be available in 2014 instead of the 2013. essay on 18,000 patients, closely followed and called IMPROVE-IT, it was designed to assess whether combining Zetia with the oldest of so-called Merck cholesterol […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-33369","post","type-post","status-publish","format-standard","hentry","category-allgemeine","et-doesnt-have-format-content","et_post_format-et-post-format-standard"],"_links":{"self":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/33369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/comments?post=33369"}],"version-history":[{"count":0,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/posts\/33369\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/media?parent=33369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/categories?post=33369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.best-dentist-dentistry.com\/de\/wp-json\/wp\/v2\/tags?post=33369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}